S 42909

Drug Profile

S 42909

Alternative Names: S-42909

Latest Information Update: 30 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Servier
  • Developer ILKOS THERAPEUTICS; Servier; Servier Canada
  • Class Antiulcers; Polyphenols; Small molecules
  • Mechanism of Action Matrix metalloproteinase 2 inhibitors; NADPH oxidase inhibitors; Plasminogen activator inhibitor-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Leg ulcer
  • Phase I Wounds

Most Recent Events

  • 01 Aug 2017 Phase-II clinical trials in Leg ulcer (In adults, In the elderly) in Spain, Austria, Canada (PO) (NCT03077165) (EudraCT2016-004143-36)
  • 29 Dec 2016 Adverse events and pharmacodynamics data from a preclinical trial in Wound healing released by Institut de Recherches Internationales SERVIER
  • 26 Sep 2016 Ilkos Therapeutic plans a phase IIa trial for Leg ulcer (In adults, In elderly) in North America and Europe (PO) (NCT03077165)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top